Key Highlights

  • Third quarter loss per share was USD 1.81 against an estimated USD 1.27 loss, and no Revenue was reported.
  • Net loss rose to USD 37.8 million from USD 23.3 million, with USD 15.0 million in CSPC license milestones.
  • Cash, cash equivalents and investments were about USD 115.3 million, and the filing says they cover at least twelve months.
  • Nine-month net loss was USD 95.8 million, and the accumulated Deficit stood at approximately USD 651.2 million.

Corbus Pharmaceuticals (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, reported a third quarter 2026 loss of USD 1.81 per share, wider than the USD 1.27 estimated loss. The company reported no revenue, against a USD 1.67 million estimate. Net loss was USD 37.8 million against USD 23.3 million a year earlier, and USD 95.8 million for the nine months against USD 58.0 million.

Research and development expense was USD 34.2 million, up USD 13.4 million, or 64%. Upfront payments and clinical milestones under the license agreement with CSPC accounted for USD 15.0 million of Research and Development expense in the quarter and USD 25.0 million for the nine months. General and administrative expense was USD 4.6 million, up USD 1.0 million, or 29%.

Cash and Funding Position

Cash, cash equivalents and investments were approximately USD 115.3 million at September 30. The filing states this balance is sufficient to meet operating and Capital requirements for at least twelve months from the issuance of the quarterly report. The accumulated deficit was approximately USD 651.2 million, and the company notes recurring losses since inception.

Oncology Program

The pipeline includes sutantatug envedotin, a next-generation antibody drug conjugate for Nectin-4-expressing tumors, licensed from CSPC in February 2023 for development in the United States and Europe. A Phase 1/2 Western study is enrolling patients with advanced solid tumors associated with Nectin-4 expression, and its dose expansion phase is ongoing. CSPC is separately running a Phase 3 trial in cervical cancer in China.

At the 2026 American Society of Clinical Oncology meeting, the company presented updated data showing activity in the second-line setting in two HPV-driven tumor types with high Nectin-4 expression, oropharyngeal squamous cell carcinoma and cervical cancer. The data came from an April 1, 2026 cut covering a safety population of 317 patients across tumor types and doses, with 75 head and neck and 72 cervical cancer patients at the relevant dose.

In obesity, CRB-913 is an orally delivered, highly peripherally restricted cannabinoid type 1 inverse agonist being developed for obesity. The company lists it alongside the oncology candidate as the second pillar of its pipeline, which it describes as focused on bringing well-understood biological pathways into new therapies.

Items to Follow

The next data from the dose expansion phase, development milestones owed under the CSPC agreement, spending growth in research and the cash balance against the twelve-month statement are the figures to follow. Net loss growth reflects both the milestone charges and wider spending, so quarterly comparisons are affected by the timing of those payments. Of research and development expense, about 13% in the quarter and 19% for the nine months was recorded in foreign entities, against 40% and 37% a year earlier.